Governmental or Regulatory Activity

Fosun Pharma’s Global Ambitions: Innovation-Driven Expansion in 2025

12 hours ago talkbio0Tagged Fosun Pharma, Global Expansion, innovative drugs, Licensing

Fosun Pharma; global expansion; innovative drugs; 2025 results; licensing deals

Cityblock Health Appoints New CTO and Tech-Focused Board Members to Accelerate AI-Driven Care

1 day ago talkbio0Tagged Alberto Lopez Toledo, board members, Carboxyamidotriazole Orotate, Cityblock Health, Medicaid

Cityblock Health; CTO; Alberto Lopez Toledo; board members; AI; Medicaid

2025 FDA staff cuts and their impact on new drug review timelines

1 week ago talkbio0Tagged 2025, CHARGE Syndrome, Drug Approval, drug review, HHS, layoffs, PDUFA, Programs - Publication Format, regulatory timelines, RFK gene, Staff, TimeLine Fluoride Releasing Resin, United States Food and Drug Administration, user fee, Workforce

FDA layoffs 2025; drug review timelines; user fee programs; HHS staff cuts; RFK Jr. layoffs; PDUFA; regulatory timelines; drug approvals; FDA workforce reductions

2025 FDA staff cuts and their impact on new drug review timelines

1 week ago talkbio0Tagged 2025, CHARGE Syndrome, Drug Approval, drug review, HHS, layoffs, PDUFA, Programs - Publication Format, regulatory timelines, RFK gene, Staff, TimeLine Fluoride Releasing Resin, United States Food and Drug Administration, user fee, Workforce

FDA layoffs 2025; drug review timelines; user fee programs; HHS staff cuts; RFK Jr. layoffs; PDUFA; regulatory timelines; drug approvals; FDA workforce reductions

2025 FDA staff cuts and their impact on new drug review timelines

1 week ago talkbio0Tagged 2025, CHARGE Syndrome, Drug Approval, drug review, HHS, layoffs, PDUFA, Programs - Publication Format, regulatory timelines, RFK gene, Staff, TimeLine Fluoride Releasing Resin, United States Food and Drug Administration, user fee, Workforce

FDA layoffs 2025; drug review timelines; user fee programs; HHS staff cuts; RFK Jr. layoffs; PDUFA; regulatory timelines; drug approvals; FDA workforce reductions

2025 FDA staff cuts and their impact on new drug review timelines

1 week ago talkbio0Tagged 2025, CHARGE Syndrome, Drug Approval, drug review, HHS, layoffs, PDUFA, Programs - Publication Format, regulatory timelines, RFK gene, Staff, TimeLine Fluoride Releasing Resin, United States Food and Drug Administration, user fee, Workforce

FDA layoffs 2025; drug review timelines; user fee programs; HHS staff cuts; RFK Jr. layoffs; PDUFA; regulatory timelines; drug approvals; FDA workforce reductions

FDA Policy Tracker: 2025 Was a Year of Change

2 weeks ago talkbio0Tagged 2025, Drug Approval, Food Safety, GRAS Reform, Improvements, Mental Recall, Trump administration, United States Food and Drug Administration

FDA; 2025; Trump Administration; Food Safety; FSMA 204; GRAS Reform; Drug Approvals; Recall Improvements

Drugmakers with White House MFN Deals Claim Exemption from Proposed Medicare Pricing Tests

3 weeks ago talkbio0Tagged deals, drug price, exemptions, Medicare, MFN, pharmaceutical companies, Pricing, Trump administration

MFN pricing; Trump administration; Medicare pricing; drug pricing deals; exemptions; pharmaceutical companies

Jim Lang Appointed to the Board of Directors of Halozyme Therapeutics

4 weeks ago talkbio0Tagged Appointments, Bench International, Biological Factors, BioVie, board of directors, Corporate governance, drug delivery platform, election, Halozyme Therapeutics, Jim Lang

Jim Lang; Halozyme Therapeutics; Board of Directors; appointment; election; Bench International; biopharmaceutical; drug delivery platform; corporate governance; OptimizeRx; BioVie

FDA Advances Real-World Data Use and Early-Phase Trial Reforms to Accelerate Drug Approvals

1 month ago talkbio0Tagged Drug Approval, early-phase trials, real-world data, real-world evidence, Real-world Evidence, RWE, Transplant Registry Unified Management Program, Trump, United States Food and Drug Administration

FDA; real-world data; real-world evidence; RWE; early-phase trials; drug approval; Marty Makary; Trump